<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Lunit Inc. — News on 6ix</title>
<link>https://6ix.com/company/lunit-inc</link>
<description>Latest news and press releases for Lunit Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 16 Apr 2026 12:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/lunit-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6836309078dffbe2df147ae2.webp</url>
<title>Lunit Inc.</title>
<link>https://6ix.com/company/lunit-inc</link>
</image>
<item>
<title>Lunit Surpasses 330+ Sites and 1M Annual Screenings as Breast Imaging AI Moves into Clinical Practice</title>
<link>https://6ix.com/company/lunit-inc/news/lunit-surpasses-330-sites-and-1m-annual-screenings-as-breast-imaging-ai-moves-into-clinical-practice</link>
<guid isPermaLink="true">https://6ix.com/company/lunit-inc/news/lunit-surpasses-330-sites-and-1m-annual-screenings-as-breast-imaging-ai-moves-into-clinical-practice</guid>
<pubDate>Thu, 16 Apr 2026 12:00:00 GMT</pubDate>
<description>At the Society of Breast Imaging (SBI) Annual Symposium, Lunit (KRX:328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced accelerating clinical adoption across the U.S., a full-scale enterprise deployment of its AI-powered breast cancer ecosystem, and FDA clearance of its next-generation 3D mammography AI.</description>
</item>
<item>
<title>Lunit, CellCarta Announce Strategic Collaboration to Accelerate AI-Enabled Digital Pathology for Companion Diagnostic Programs</title>
<link>https://6ix.com/company/lunit-inc/news/lunit-cellcarta-announce-strategic-collaboration-to-accelerate-ai-enabled-digital-pathology-for-companion-diagnostic-programs</link>
<guid isPermaLink="true">https://6ix.com/company/lunit-inc/news/lunit-cellcarta-announce-strategic-collaboration-to-accelerate-ai-enabled-digital-pathology-for-companion-diagnostic-programs</guid>
<pubDate>Mon, 30 Mar 2026 07:15:00 GMT</pubDate>
<description>Lunit (KRX: 328130), a leading provider of AI for cancer diagnostics and precision oncology, and CellCarta, a leading global contract research organization (CRO) laboratory to the biopharmaceutical industry, today announced a strategic partnership to accelerate adoption of AI-enabled digital pathology workflows across translational research, clinical trials and companion diagnostic (CDx) programs.</description>
</item>
<item>
<title>Lunit AI Maps the Tumor-Immune Landscape to Predict Immunotherapy Response and Discover New Antibody Targets at SITC 2025</title>
<link>https://6ix.com/company/lunit-inc/news/lunit-ai-maps-the-tumor-immune-landscape-to-predict-immunotherapy-response-and-discover-new-antibody-targets-at-sitc-2025</link>
<guid isPermaLink="true">https://6ix.com/company/lunit-inc/news/lunit-ai-maps-the-tumor-immune-landscape-to-predict-immunotherapy-response-and-discover-new-antibody-targets-at-sitc-2025</guid>
<pubDate>Fri, 07 Nov 2025 14:05:00 GMT</pubDate>
<description>Lunit (KRX:328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced the presentation of three studies at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting, taking place November 5-9 in Maryland, U.S. The findings highlight how Lunit's AI-powered digital pathology technologies—Lunit SCOPE IO® and Lunit SCOPE® uIHC—can advance precision oncology by uncovering predictive immune signatures and guiding antibody-based drug development.</description>
</item>
<item>
<title>Volpara Now Operates Under Lunit Brand, Advancing a Unified Vision for AI Cancer Intelligence</title>
<link>https://6ix.com/company/lunit-inc/news/volpara-now-operates-under-lunit-brand-advancing-a-unified-vision-for-ai-cancer-intelligence</link>
<guid isPermaLink="true">https://6ix.com/company/lunit-inc/news/volpara-now-operates-under-lunit-brand-advancing-a-unified-vision-for-ai-cancer-intelligence</guid>
<pubDate>Thu, 06 Nov 2025 14:00:00 GMT</pubDate>
<description>Lunit (KRX: 328130), a leading provider of AI for cancer diagnostics and therapeutics, today announced that Volpara Health Technologies will now operate under the Lunit brand, introducing a unified global identity that merges their complementary strengths in breast health and AI innovation.</description>
</item>
<item>
<title>Lunit AI Predicts Immunotherapy Outcome in Colorectal, Kidney, and Lung Cancer at ESMO 2025</title>
<link>https://6ix.com/company/lunit-inc/news/lunit-ai-predicts-immunotherapy-outcome-in-colorectal-kidney-and-lung-cancer-at-esmo-2025</link>
<guid isPermaLink="true">https://6ix.com/company/lunit-inc/news/lunit-ai-predicts-immunotherapy-outcome-in-colorectal-kidney-and-lung-cancer-at-esmo-2025</guid>
<pubDate>Tue, 14 Oct 2025 13:00:00 GMT</pubDate>
<description>Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, today announced the presentation of three studies at the European Society for Medical Oncology (ESMO) Congress 2025, taking place October 17–21 in Berlin, Germany. All three studies highlight how Lunit's AI pathology solution, Lunit SCOPE IO®, can identify biomarkers that predict response to immune checkpoint inhibitors (ICIs), offering new potential to guide more effective and personalized cancer treatment.</description>
</item>
<item>
<title>Lunit, CellCarta Announce Global Alliance to Expand Access to Digital Pathology AI for Clinical Trials</title>
<link>https://6ix.com/company/lunit-inc/news/lunit-cellcarta-announce-global-alliance-to-expand-access-to-digital-pathology-ai-for-clinical-trials</link>
<guid isPermaLink="true">https://6ix.com/company/lunit-inc/news/lunit-cellcarta-announce-global-alliance-to-expand-access-to-digital-pathology-ai-for-clinical-trials</guid>
<pubDate>Wed, 24 Sep 2025 13:00:00 GMT</pubDate>
<description>Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and biomarkers for oncology therapeutics, today announced a strategic partnership with CellCarta, a globally recognized provider of CRO laboratory services for pharmaceutical research and development. Under the partnership, Lunit's AI pathology solutions will be offered as part of CellCarta's services for global clinical trials, making it easier for pharma sponsors to adopt AI-powered analysis within existing trial workflows.</description>
</item>
<item>
<title>Lunit and Agilent Technologies Announce Collaboration to Enhance Development of Companion Diagnostic Solutions Powered with AI for Precision Medicine</title>
<link>https://6ix.com/company/lunit-inc/news/lunit-and-agilent-technologies-announce-collaboration-to-enhance-development-of-companion-diagnostic-solutions-powered-with-ai-for-precision-medicine</link>
<guid isPermaLink="true">https://6ix.com/company/lunit-inc/news/lunit-and-agilent-technologies-announce-collaboration-to-enhance-development-of-companion-diagnostic-solutions-powered-with-ai-for-precision-medicine</guid>
<pubDate>Mon, 22 Sep 2025 13:00:00 GMT</pubDate>
<description>Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, and Agilent Technologies Inc. (NYSE: A), a global leader in life sciences, diagnostics, and applied chemical markets, today announced a nonexclusive collaboration to develop AI-based companion diagnostic solutions. The collaboration will leverage Lunit's AI technology and Agilent's expertise in tissue-based companion diagnostics to create advanced solutions that meet the demand of novel and complex biomarker</description>
</item>
<item>
<title>Lunit Showcases AI-Powered Cancer Ecosystem at APEC High-Level Meeting on Health and the Economy and World Bio Summit 2025</title>
<link>https://6ix.com/company/lunit-inc/news/lunit-showcases-ai-powered-cancer-ecosystem-at-apec-high-level-meeting-on-health-and-the-economy-and-world-bio-summit-2025</link>
<guid isPermaLink="true">https://6ix.com/company/lunit-inc/news/lunit-showcases-ai-powered-cancer-ecosystem-at-apec-high-level-meeting-on-health-and-the-economy-and-world-bio-summit-2025</guid>
<pubDate>Tue, 16 Sep 2025 13:00:00 GMT</pubDate>
<description>Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, today announced its participation in two major global health gatherings taking place in Seoul this week: the 15th APEC High-Level Meeting on Health and the Economy (APEC HLMHE) and the World Bio Summit 2025 (WBS 2025).</description>
</item>
<item>
<title>Lunit Awarded Major National Tender in France, Expanding Access to Breast AI in Public Hospitals</title>
<link>https://6ix.com/company/lunit-inc/news/lunit-awarded-major-national-tender-in-france-expanding-access-to-breast-ai-in-public-hospitals</link>
<guid isPermaLink="true">https://6ix.com/company/lunit-inc/news/lunit-awarded-major-national-tender-in-france-expanding-access-to-breast-ai-in-public-hospitals</guid>
<pubDate>Thu, 11 Sep 2025 13:00:00 GMT</pubDate>
<description>Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, today announced that its breast imaging AI solutions have been selected under a national framework agreement led by UniHA, the largest central public procurement body for French hospitals.</description>
</item>
<item>
<title>Lunit Selected as Exclusive AI Partner for Spain's Valencian Community Breast Screening Program</title>
<link>https://6ix.com/company/lunit-inc/news/lunit-selected-as-exclusive-ai-partner-for-spains-valencian-community-breast-screening-program</link>
<guid isPermaLink="true">https://6ix.com/company/lunit-inc/news/lunit-selected-as-exclusive-ai-partner-for-spains-valencian-community-breast-screening-program</guid>
<pubDate>Tue, 02 Sep 2025 13:00:00 GMT</pubDate>
<description>Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, today announced that its solutions have been selected as the exclusive AI tools for the breast cancer screening program of the Valencian Community, one of Spain's largest and most progressive healthcare regions.</description>
</item>
<item>
<title>Lunit's AI Now Powers Cancer Screening for Over 14% of Italy's Population Through Public Health System</title>
<link>https://6ix.com/company/lunit-inc/news/lunits-ai-now-powers-cancer-screening-for-over-14percent-of-italys-population-through-public-health-system</link>
<guid isPermaLink="true">https://6ix.com/company/lunit-inc/news/lunits-ai-now-powers-cancer-screening-for-over-14percent-of-italys-population-through-public-health-system</guid>
<pubDate>Tue, 26 Aug 2025 13:00:00 GMT</pubDate>
<description>Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, today announced a significant expansion of its footprint in Italy's public healthcare system. As of June 2025, more than 10 Local Health Authorities—commonly known as ASL (Azienda Sanitaria Locale)—are using Lunit's AI solutions to enhance cancer screening and optimize imaging workflow. These ASLs collectively serve a population of over 8.5 million, accounting for approximately 14% of Italy's total populatio</description>
</item>
<item>
<title>Lunit and Microsoft Collaborate to Advance AI-Driven Cancer Diagnosis</title>
<link>https://6ix.com/company/lunit-inc/news/lunit-and-microsoft-collaborate-to-advance-ai-driven-cancer-diagnosis</link>
<guid isPermaLink="true">https://6ix.com/company/lunit-inc/news/lunit-and-microsoft-collaborate-to-advance-ai-driven-cancer-diagnosis</guid>
<pubDate>Wed, 02 Jul 2025 13:00:00 GMT</pubDate>
<description>Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, today announced a collaboration with Microsoft to accelerate the delivery of AI-powered healthcare solutions. In conjunction with their recent acquisition of Volpara, a Microsoft Industry Health Certified Partner, this collaboration will give health professionals globally access to tools that will assist in the detection of cancer.</description>
</item>
<item>
<title>Lunit AI Used Again for Mass Screening During 2025 Hajj Season in Saudi Arabia</title>
<link>https://6ix.com/company/lunit-inc/news/lunit-ai-used-again-for-mass-screening-during-2025-hajj-season-in-saudi-arabia</link>
<guid isPermaLink="true">https://6ix.com/company/lunit-inc/news/lunit-ai-used-again-for-mass-screening-during-2025-hajj-season-in-saudi-arabia</guid>
<pubDate>Thu, 12 Jun 2025 15:04:00 GMT</pubDate>
<description>Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, today announced that its AI-based chest X-ray analysis solution, Lunit INSIGHT CXR, was used again by the Saudi Government and Seha Virtual Hospital (SVH) to support large-scale screening during the 2025 Hajj season, which took place June 4–9.</description>
</item>
<item>
<title>Lunit Launches Enhanced Lunit INSIGHT CXR4, Secures CE MDR Certification for Expanded AI Capabilities</title>
<link>https://6ix.com/company/lunit-inc/news/lunit-launches-enhanced-lunit-insight-cxr4-secures-ce-mdr-certification-for-expanded-ai-capabilities</link>
<guid isPermaLink="true">https://6ix.com/company/lunit-inc/news/lunit-launches-enhanced-lunit-insight-cxr4-secures-ce-mdr-certification-for-expanded-ai-capabilities</guid>
<pubDate>Wed, 28 May 2025 13:00:00 GMT</pubDate>
<description>Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, today announced the official launch and CE certification under the Medical Device Regulation (MDR) of Lunit INSIGHT CXR4, its next-generation chest X-ray analysis solution.</description>
</item>
<item>
<title>Lunit Highlights AI's Role in Advancing Precision Oncology at ASCO 2025 with 12 Studies</title>
<link>https://6ix.com/company/lunit-inc/news/lunit-highlights-ais-role-in-advancing-precision-oncology-at-asco-2025-with-12-studies</link>
<guid isPermaLink="true">https://6ix.com/company/lunit-inc/news/lunit-highlights-ais-role-in-advancing-precision-oncology-at-asco-2025-with-12-studies</guid>
<pubDate>Mon, 26 May 2025 13:00:00 GMT</pubDate>
<description>Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, today announced that 12 studies featuring its AI-powered digital pathology solution will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30–June 3 in Chicago, IL. Of these, 11 studies will be presented as posters and one as an online publication.</description>
</item>
<item>
<title>Lunit Surpasses 1 Million Mammograms in U.S. One Year After Volpara Acquisition</title>
<link>https://6ix.com/company/lunit-inc/news/lunit-surpasses-1-million-mammograms-in-us-one-year-after-volpara-acquisition</link>
<guid isPermaLink="true">https://6ix.com/company/lunit-inc/news/lunit-surpasses-1-million-mammograms-in-us-one-year-after-volpara-acquisition</guid>
<pubDate>Mon, 19 May 2025 13:00:00 GMT</pubDate>
<description>Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, today announced major milestones in the United States, one year after its acquisition of Volpara Health Technologies.</description>
</item>
<item>
<title>Lunit to Power Germany's Largest Private Radiology Network with AI Imaging</title>
<link>https://6ix.com/company/lunit-inc/news/lunit-to-power-germanys-largest-private-radiology-network-with-ai-imaging</link>
<guid isPermaLink="true">https://6ix.com/company/lunit-inc/news/lunit-to-power-germanys-largest-private-radiology-network-with-ai-imaging</guid>
<pubDate>Wed, 07 May 2025 13:00:00 GMT</pubDate>
<description>Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, today announced a strategic partnership with Starvision Service GmbH, Germany's largest private radiology network. Through a newly signed framework agreement, Lunit's AI imaging solutions will be deployed across Starvision's expansive network of radiological practices.</description>
</item>
<item>
<title>Lunit Showcases AI Pathology Advances in Cancer Research from Rare to Common Tumors at AACR 2025</title>
<link>https://6ix.com/company/lunit-inc/news/lunit-showcases-ai-pathology-advances-in-cancer-research-from-rare-to-common-tumors-at-aacr-2025</link>
<guid isPermaLink="true">https://6ix.com/company/lunit-inc/news/lunit-showcases-ai-pathology-advances-in-cancer-research-from-rare-to-common-tumors-at-aacr-2025</guid>
<pubDate>Tue, 22 Apr 2025 13:00:00 GMT</pubDate>
<description>Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the presentation of seven posters at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25–30 in Chicago, Illinois. The presentations introduce Lunit's latest research in AI-based histopathology, featuring studies powered by the Lunit SCOPE® suite across a range of cancers—from rare salivary gland tumors to common types like lung canc</description>
</item>
<item>
<title>Lunit Study in Radiology Highlights Trust Gap Between Radiologists and AI in Breast Cancer Screening</title>
<link>https://6ix.com/company/lunit-inc/news/lunit-study-in-radiology-highlights-trust-gap-between-radiologists-and-ai-in-breast-cancer-screening</link>
<guid isPermaLink="true">https://6ix.com/company/lunit-inc/news/lunit-study-in-radiology-highlights-trust-gap-between-radiologists-and-ai-in-breast-cancer-screening</guid>
<pubDate>Wed, 09 Apr 2025 13:00:00 GMT</pubDate>
<description>Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the publication of a new study in Radiology (RSNA's flagship journal), highlighting how radiologists interact with AI in real-world breast cancer screening.</description>
</item>
<item>
<title>Lunit Announces Partnership with the National Cancer Institute to Advance AI-Powered Biomarker Research</title>
<link>https://6ix.com/company/lunit-inc/news/lunit-announces-partnership-with-the-national-cancer-institute-to-advance-ai-powered-biomarker-research</link>
<guid isPermaLink="true">https://6ix.com/company/lunit-inc/news/lunit-announces-partnership-with-the-national-cancer-institute-to-advance-ai-powered-biomarker-research</guid>
<pubDate>Mon, 31 Mar 2025 13:00:00 GMT</pubDate>
<description>Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced a collaboration with the National Cancer Institute (NCI), part of the U.S. National Institutes of Health (NIH), to explore innovative applications of AI in cancer research. This collaboration aims to advance research into the tumor microenvironment and immune phenotyping, analyzing NCI data to uncover insights that could drive personalized cancer care.</description>
</item>
</channel>
</rss>